Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy

Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival

(2012) Y. Sawada et al.   CLINICAL CANCER RESEARCH

Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary

(2012) Masashi Takano et al.   International Journal of Clinical Oncology

Postrecurrent Oncologic Outcome of Patients With Ovarian Clear Cell Carcinoma

(2012) Hiroaki Kajiyama et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma

(2011) Shiro Suzuki et al.   CANCER SCIENCE

Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers

(2008) John K. Chan et al.   GYNECOLOGIC ONCOLOGY

Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma

(2008) Sarit Aviel-Ronen et al.   MODERN PATHOLOGY